One-year results from the vaccination campaign against COVID-19 infection in 47 million individuals with severe mental disorders and other chronic diseases

Abstract

Severe mental disorders have been associated with increased COVID-19 mortality. The aim of this study was to evaluate the results of the vaccination campaign against COVID-19 after 1 year using exhaustive population-based data. In this nationwide population-based study, we used data from the French national medico-administrative database (SNDS) and the COVID Vaccine teleservice from January 4, 2021 (date of activation of the teleservice) to January 30th, 2022. As of January 30th, 2022, the rate of first injection in France was 80.2% (54 million people) and the rate of booster vaccination was 78.3% (52.7 million people). Except for opioid use disorder, all individuals with chronic illnesses or risk factors for poor COVID-19 outcome (e.g., smoking and obesity) had higher rates of vaccination than the general population (from 83.4 to 94.5% vs. 78.3%). However, the four diseases ranking last for both initial and booster vaccinations were mental disorders: alcohol use disorders (86 and 84.3%), neurodevelopmental psychiatric disorders (85.3 and 83.7%), schizophrenia-spectrum disorder (85 and 83.4%) and opioid use disorders (72.9 and 69.4%). Except for opioid disorders, all patients with mental disorders had higher rates of vaccination compared to the general population. However, these rates were lower than other chronic diseases at risk of severe COVID-19 outcomes. Vaccination campaigns must redouble their efforts to improve vaccination penetration in patients with mental disorders.

Seroprevalence of SARS-CoV-2 and humoral immune responses to mRNA vaccines among people who use drugs - In the light of tailored mitigating strategies

“…However, the percentage of PWUD who received dose 2 is still on level with the total Norwegian population (19). In contrast, several studies have found a lower cumulative vaccine uptake mong PWUD compared to the general population (51)(52)(53)(54)(55)(56). Some studies suggest that this can be explained by hesitancy towards the vaccines among PWUD (52,54).…”

Opiate maintenance patients’ attitudes and self-reported adherence to protective measures against SARS-CoV-2 infections

“…Harm-reduction measures such as needle sharing programs indeed postulate that their target group is willing and proficient to adopt healthy behaviors (38). Finally, the huge differences in vaccination rates reported for different countries such as the France, USA, Spain, and Mexico [e.g., (19)(20)(21)(22)], may suggest a relevant influence of context factors such as the characteristics of the national/local health system.…”

“…Regarding COVID-19, studies focusing on OMTP showed considerable variations regarding vaccine hesitancy during the first year of the pandemic: studies from Australia, USA, and Norway showed 20–40% rates of self-reported vaccination rejection ( 16–18 ), whereas studies from France, Spain, Australia, USA, and Mexico showed hesitancy in >70% ( 19 , 20 ), 49% ( 15 ), 38% ( 21 ), and 38% ( 22 ), respectively. What these studies have in common is that vaccination completion rates in PWID were much lower than the rates that were observed in the surrounding general adult population.…”

‘It’s a fragile open door’—enhancing COVID-19 vaccination rates in people receiving treatment for substance use disorder

“…Although the dual vaccination rate achieved in this study of 86.7% was slightly lower than the general population, they are substantially higher than national and international rates. In total, ~50% of Australian NSP attendees have received dual vaccination, 9 while 69.4% of people with Opioid Use Disorder (OUD) in France 25 and 71% of people attending a Spanish OTP clinic had double vaccination. 6 …”